Madrigal Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $311,337 | $321,083 | $287,268 | $212,802 |
Gross Profit | 284,490 | 296,635 | 269,146 | 203,737 |
EBITDA | -92,723 | -49,886 | -106,381 | -38,640 |
EBIT | -93,109 | -50,278 | -106,739 | -39,017 |
Net Income | -94,391 | -58,575 | -114,190 | -42,281 |
Net Change In Cash | 311,337 | 321,083 | 287,268 | 212,802 |
Free Cash Flow | -171,284 | -133,070 | 78,993 | -47,052 |
Cash | 232,188 | 198,693 | 295,694 | 186,193 |
Basic Shares | 29,032 | 22,434 | 22,482 | 22,207 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $958,403 | $180,133 | $0 | $0 |
Gross Profit | 902,255 | 173,900 | -527 | -467 |
EBITDA | -264,469 | -450,125 | -360,391 | -290,919 |
EBIT | -265,975 | -451,221 | -360,918 | -291,386 |
Net Income | -288,284 | -465,892 | -373,630 | -295,350 |
Net Change In Cash | 958,403 | 180,133 | 0 | 0 |
Cost of Revenue | 295,280 | |||
Free Cash Flow | -190,020 | -457,034 | -325,709 | -225,074 |
Cash | 198,693 | 100,019 | 99,915 | 331,549 |
Basic Shares | 22,434 | 21,272 | 18,688 | 17,137 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$1.38 |
2025-12-31 | -$2.57 |
2025-09-30 | -$4.95 |
2025-06-30 | -$1.90 |